Unlike the two currently authorised vaccines, J&J’sdoes not require a second shot or need to be shipped frozen.
Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for emergency use.
The drugmaker’s application to the U.S. Food and Drug Administration (FDA) follows its Jan. 29 report in which it said the vaccine had a 66% rate of preventing infections in its large global trial.
Also read: EU approves Pfizer-BioNTech coronavirus vaccine
J&J’s single-shot vaccine could help boost supply and simplify the U.S. immunization campaign, amid concerns of fresh surges due to the more contagious UK coronavirus variant and the potential of lower vaccine efficacy against the variant that first emerged in South Africa.
Unlike the two currently authorised vaccines from PfizerInc/BioNTech SE and Moderna Inc, J&J’sdoes not require a second shot or need to be shipped frozen.
After the company’s application, regulators will…
